Mifobate 是一种有效且特异性的PPARγ拮抗剂，可选择性抑制噻唑烷二酮 (TZD) 诱导的 PPARγ 转录活性，IC50为140 μM，具有抗肥胖和抗糖尿病作用。

Mifobate is a potent and specific antagonist of PPARγ. Mifobate shows antiobesity, antidiabetic and antiatherosclerotic effects[1].

SR-202 is a new synthetic PPARgamma antagonist,, which inhibits both TZD-stimulated recruitment of the coactivator steroid receptor coactivator-1 and TZD-induced transcriptional activity of the receptor.?In cell culture, SR-202 efficiently antagonizes hormone- and TZD-induced adipocyte differentiation[1].

In vivo, decreasing PPARgamma activity, either by treatment with SR-202 or by invalidation of one allele of the PPARgamma gene, leads to a reduction of both high fat diet-induced adipocyte hypertrophy and insulin resistance.?These effects are accompanied by a smaller size of the adipocytes and a reduction of TNFalpha and leptin secretion.?Treatment with SR-202 also dramatically improves insulin sensitivity in the diabetic ob/ob mice[1].

76541-72-5

C11H17ClO7P2

358.65

SR-202;米福贝特

H2O:35.87 mg/mL (100.01 mM),Need ultrasonic and warming
Powder: -20°C for 3 years
In solvent: -80°C for 2 years